Sleep Peptide Research

DSIP Peptide Benefits and Side Effects: Research Data

What delta sleep-inducing peptide studies report on deep sleep and insomnia, why independent trials disagree, what is known about safety, and where DSIP stands with regulators.

·
Fact-checked · Reviewed by Remy Research Editorial Board
Update History ▾
October 27, 2026: Initial publication, built from FDA’s 2026 emideltide briefing document, FDA’s Category 2 page, the WADA Prohibited List and the fact-checked DSIP source set.
Research-use-only framing applied throughout in line with Remy editorial standards.
TL;DR — Research Summary

The DSIP peptide benefits most often claimed (deep restorative sleep, better sleep quality, faster sleep onset and stress relief) rest on small studies from the 1970s and 1980s, most of them from the Swiss group that discovered it. Rabbit work showed more delta-wave EEG activity, and the discoverers reported better sleep in people with insomnia.[1][2] Independent double-blind trials found little or no benefit, a rat replication failed, and in 2026 FDA called the insomnia evidence “inconclusive and at best preliminary.”[3][4][5][6]

DSIP side effects in the short studies were mostly mild, such as headache and warmth, but long-term safety has never been studied.[6] DSIP is not FDA-approved, and in July 2026 FDA’s advisory committee voted 7–6 against adding it to the US compounding list.[7] Remy Research supplies DSIP for in-vitro laboratory research only.

Compliance note: this page is a research review, not a treatment guide. It does not provide human-use dosing, therapeutic recommendations, or any clinical-use instructions, and should be read in the same non-therapeutic frame required across Remy's research content.

What Is DSIP (Delta Sleep Inducing Peptide)?

DSIP, short for delta sleep-inducing peptide, is a nine-amino-acid peptide (a nonapeptide) with the sequence Trp-Ala-Gly-Gly-Asp-Ala-Ser-Gly-Glu. Its chemical structure is listed in PubChem as C35H48N10O15, molecular weight about 848.8 g/mol, CAS 62568-57-4.[8] Its international nonproprietary name, proposed by WHO in 1993, is emideltide.[9]

The story began in 1964, when dialysed cerebral venous blood from sleeping rabbits, whose sleep had been induced by brain stimulation, produced sleep in other rabbits.[10] In 1977 the Basel group of Schoenenberger and Monnier isolated the responsible peptide: given into the brain ventricles of rabbits, synthetic DSIP increased delta and spindle EEG patterns, while related fragments did not.[1]

DSIP is often called a naturally occurring nonapeptide or naturally occurring neuropeptide, but that is unresolved. DSIP-like material has been reported in blood and cerebrospinal fluid, yet no gene or precursor has been found, and a brain protein detected by anti-DSIP antibodies proved unrelated in sequence.[11][12] In the body it lasts minutes: half-lives in animals were about two to four minutes, and blood peptidases break it down rapidly.[13][14]

How DSIP Is Thought to Work: Proposed Mechanisms

FDA’s 2026 review states that the primary mechanisms of action and pharmacokinetic profile of DSIP are unknown.[6] No receptor has been identified, so the precise mechanism remains open.[11] The proposed pathways rest on animal models and in-vitro studies:

The opioid finding comes mainly from one Japanese group and the glutamate and GABA findings from a small Russian network. The conflicting human endocrine studies mean that claims of neuroendocrine regulation, effects on neuroendocrine systems or a calmer stress response are not established. In short, how DSIP would work in the body remains unknown.

Potential DSIP Peptide Benefits in Research

Sleep optimization marketing often says DSIP appears to restore natural sleep architecture. The table tests each claimed benefit of the delta sleep inducing peptide against what the studies actually reported and the type of evidence.

DSIP — Claimed Benefits and the Evidence Behind Them
Claimed benefit What was reported Evidence type
Deep sleep (delta) More delta and spindle EEG activity in rabbits Animal
Sleep in rats No significant rise in sleep or delta activity Animal (null)
Insomnia Better sleep in small discoverer-group studies Human, small trials
Insomnia, blinded Little or no benefit over placebo Human, controlled
Sleep timing Phase advanced in one case of delayed sleep Human case report
Withdrawal Improvement reported without control groups Human, open studies

Delta Sleep and Slow Wave Sleep in Animal Models

The name comes from the rabbit result: DSIP increased delta wave activity, the slow waves of deep slow wave sleep, in 58 rabbits studied double-blind; this delta wave sleep effect is where the name delta sleep inducing peptide comes from.[1] A 1980 rat study found no significant increase in sleep or delta activity and concluded that DSIP does not qualify as a specific sleep-promoting substance.[5] In a 1988 rat study, antibodies against DSIP blocked the rise in slow wave sleep and growth hormone release that normally follows sleep deprivation, which the authors read as a possible role in natural sleep.[19]

Sleep Quality and Sleep Onset in People with Insomnia

Early studies came from the discovery group. In a 1981 double-blind crossover study of six healthy volunteers, total sleep rose by 59% in the two hours after DSIP compared with placebo, and the next night showed shorter sleep onset and better sleep efficiency; the authors saw no sedation in the classic pharmacological sense.[20] A 1984 summary reported improved sleep in two studies and a gradual normalisation of sleep structure with repeated treatment.[21] In 1987 a 7-night study in 14 chronic insomnia patients reported that the efficiency of night sleep reached the level of normal controls and that daytime alertness improved; FDA notes it had no concurrent placebo arm and used an external control group.[2][6]

The independent trials did not confirm a sleep quality improvement. A 1987 double-blind crossover study in insomnia patients found no significant differences from placebo; slow wave sleep and REM sleep were unchanged, and the authors judged any improvement of little clinical significance.[3] A 1992 double-blind study in 16 chronic insomnia patients found slightly higher sleep efficiency and reduced sleep latency, but the effects were weak, partly explained by a change in the placebo group, and subjective sleep quality did not change.[4] No study has shown reduced sleep onset latency or better subjective sleep quality with DSIP in a modern trial.

Circadian Rhythm and Sleep Patterns

Claims about the circadian rhythm rest on one case: a woman with delayed sleep phase insomnia and benzodiazepine dependence, studied for a week under polygraphic control, advanced her main sleep phase by five hours and stopped her sleeping pill.[22] A single uncontrolled case cannot show an effect on circadian rhythm disorders or shift work sleep patterns.

Withdrawal Symptoms

Open studies in the 1980s and 1990s reported improvement in alcohol and opiate withdrawal symptoms, but they had no control groups, and in a 1998 opioid study only two of seven patients completed the study.[23][24]

Clinical Studies in Humans: Small, Old and Mixed

FDA counted 209 people given DSIP in studies lasting 1 to 15 days.[6] The only later randomised human study, published in 2009 in 24 surgical patients, tested the idea that DSIP crosses the blood brain barrier and deepens anaesthesia; instead it lightened anaesthetic depth and reduced delta activity, the opposite of what its name suggests.[25] No DSIP study is registered on ClinicalTrials.gov.[26] The evidence base is therefore small, dated and dominated by one group.

DSIP Side Effects and Safety

What the published studies and FDA’s 2026 review report:

FDA found no long-term or repeat-dose studies, and no study has examined interactions with sleep or psychiatric medications, so DSIP’s safety in humans is not established.[6]

Is DSIP FDA Approved?

Where DSIP stands as of October 28, 2026.
  • FDA approval. No. No FDA-approved drug contains emideltide.[6]
  • Compounding. FDA’s Category 2 page lists “Emideltide (DSIP)” under “nominated but withdrawn.”[28] On July 24, 2026 FDA’s advisory committee voted 7–6, with one abstention, against adding it to the compounding list, the first peptide that panel rejected.[7] An FDA interim access policy for certain peptides has been under White House review since October 14, 2026, with no final action yet.[29]
  • Russia. A DSIP-based product, Deltaran, is registered as a non-prescription preparation for stress-induced states and alcohol withdrawal, as part of combination therapy.[30]
  • Sport. DSIP is not named on WADA’s 2027 Prohibited List. Class S0 bans unapproved substances, including peptides; the Russian registration makes its status unclear.[31]
  • UAE. DSIP is not a registered medicine. Remy Research sells it for in-vitro laboratory research only, not for human use or veterinary use.

DSIP vs Other Sleep and Neuropeptide Research Compounds

DSIP is often grouped with Epitalon, a pineal tetrapeptide studied for melatonin and circadian endpoints, and with the Russian neuropeptides Selank and Semax. Each has its own small evidence base: see the Epitalon research review, the Selank research review and the Semax research review. Unlike conventional sleep medications, DSIP has no approved use and no modern trial behind it.[6]

What the DSIP Research Does Not Yet Show

DSIP for Research Purposes

Remy Research supplies DSIP for in-vitro research as the Genovare DSIP 50mg AQ pen. The product page carries its batch testing details. For the full evidence review, including the history of the Basel studies and the July 2026 FDA vote, read the DSIP research review.

Our Research Standards

This article prioritizes primary literature, FDA’s 2026 briefing document and regulator records, and gives null results and failed replications the same weight as positive ones. Where the human record is thin, we say so directly. No therapeutic, dosing or administration guidance is given. Read our editorial policy →

RP
Editorial Review

Editorial Board, Remy Research

The Remy Research Editorial Board reviews Remy's peptide research library, with a focus on analytical verification, clinical-trial interpretation, and compliance-safe scientific communication.

About the editorial team →

DSIP Benefits and Side Effects FAQ

What does DSIP stand for?

DSIP stands for delta sleep inducing peptide, named after the delta-wave EEG activity it increased in rabbits in 1977. Its WHO name is emideltide.[1][9]

What are the benefits of the DSIP peptide?

The claimed benefits are deeper sleep, better sleep quality and easier withdrawal. Small early studies reported them, but independent double-blind trials found little or no benefit, and FDA called the insomnia evidence inconclusive.[2][3][4][6]

What are the side effects of DSIP?

Short studies reported headache, warmth, heaviness and dry mouth; one withdrawal study reported low blood pressure in two patients. Long-term effects are unknown.[6][23]

Does DSIP help with sleep?

That is not established. Rabbit studies and the discoverers’ small human studies were positive, but a rat study and two independent double-blind insomnia trials were not.[5][3][4]

Is DSIP FDA approved?

No. No FDA-approved drug contains it, and in July 2026 an FDA advisory committee voted 7–6 against adding it to the compounding list.[6][7]

Is DSIP safe?

Its safety has not been established. FDA found no repeat-dose toxicity, genotoxicity, immunogenicity or abuse-liability studies.[6]

Is DSIP made naturally in the body?

That is unresolved. DSIP-like material has been reported in blood, but no gene, precursor or receptor has been found.[11]

Is DSIP approved anywhere?

Russia registers a DSIP-based non-prescription product, Deltaran, for stress-induced states and alcohol withdrawal.[30]

Sources

  1. Schoenenberger GA, Monnier M. Characterization of a delta-electroencephalogram (-sleep)-inducing peptide. Proc Natl Acad Sci U S A. 1977;74(3):1282-1286. doi: 10.1073/pnas.74.3.1282 · PMID: 265572 ↩
  2. Schneider-Helmert D. Effects of delta-sleep-inducing peptide on 24-hour sleep-wake behaviour in severe chronic insomnia. Eur Neurol. 1987;27(2):120-129. doi: 10.1159/000116143 · PMID: 3622582 ↩
  3. Monti JM, Debellis J, Alterwain P, et al. Study of delta sleep-inducing peptide efficacy in improving sleep on short-term administration to chronic insomniacs. Int J Clin Pharmacol Res. 1987;7(2):105-110. PMID: 3583493 ↩
  4. Bes F, Hofman W, Schuur J, Van Boxtel C. Effects of delta sleep-inducing peptide on sleep of chronic insomniac patients. A double-blind study. Neuropsychobiology. 1992;26(4):193-197. doi: 10.1159/000118919 · PMID: 1299794 ↩
  5. Tobler I, Borbély AA. Effect of delta sleep inducing peptide (DSIP) and arginine vasotocin (AVT) on sleep and motor activity in the rat. Waking Sleeping. 1980;4(2):139-153. PMID: 7405185 ↩
  6. U.S. Food and Drug Administration. FDA Evaluation of emideltide (free base) and emideltide acetate, briefing document for the July 23–24, 2026 Pharmacy Compounding Advisory Committee meeting, dated May 11, 2026. Checked October 28, 2026. fda.gov/media/193344 ↩
  7. Kansteiner F. Peptide adcomm Day 2: Emideltide voted down in panel’s 1st pushback. Fierce Pharma, July 24, 2026. fiercepharma.com ↩
  8. National Center for Biotechnology Information. PubChem Compound Summary for CID 68816, Delta sleep-inducing peptide. pubchem.ncbi.nlm.nih.gov/compound/68816 ↩
  9. World Health Organization. Proposed International Nonproprietary Names, List 70 (emideltide), WHO Drug Information 7(4), 1993. who.int ↩
  10. Monnier M, Hösli L. Dialysis of sleep and waking factors in blood of the rabbit. Science. 1964;146(3645):796-798. doi: 10.1126/science.146.3645.796 · PMID: 14197576 ↩
  11. Kovalzon VM, Strekalova TV. Delta sleep-inducing peptide (DSIP): a still unresolved riddle. J Neurochem. 2006;97(2):303-309. doi: 10.1111/j.1471-4159.2006.03693.x · PMID: 16539679 ↩
  12. Sillard R, Schulz-Knappe P, Vogel P, et al. A novel 77-residue peptide from porcine brain contains a leucine-zipper motif and is recognized by an antiserum to delta-sleep-inducing peptide. Eur J Biochem. 1993;216(2):429-436. doi: 10.1111/j.1432-1033.1993.tb18160.x · PMID: 8375381 ↩
  13. Kato N, Honda Y, Ebihara S, et al. Development of an enzyme immunoassay for delta sleep-inducing peptide (DSIP) and its use in the determination of the metabolic clearance rate of DSIP administered to dogs. Neuroendocrinology. 1984;39(1):39-44. doi: 10.1159/000123952 · PMID: 6379493 ↩
  14. Graf MV, Saegesser B, Schoenenberger GA. Degradation and aggregation of delta sleep-inducing peptide (DSIP) and two analogs in plasma and serum. Peptides. 1987;8(4):599-603. doi: 10.1016/0196-9781(87)90031-3 · PMID: 3628078 ↩
  15. Nakamura A, Nakashima M, Sakai K, et al. Delta-sleep-inducing peptide (DSIP) stimulates the release of immunoreactive Met-enkephalin from rat lower brainstem slices in vitro. Brain Res. 1989;481(1):165-168. doi: 10.1016/0006-8993(89)90498-8 · PMID: 2706459 ↩
  16. Grigor’ev VV, Ivanova TA, Kustova EA, et al. Effects of delta sleep-inducing peptide on pre- and postsynaptic glutamate and postsynaptic GABA receptors in neurons of the cortex, hippocampus, and cerebellum in rats. Bull Exp Biol Med. 2006;142(2):186-188. doi: 10.1007/s10517-006-0323-9 · PMID: 17369935 ↩
  17. Bjartell A, Ekman R, Bergquist S, et al. Reduction of immunoreactive ACTH in plasma following intravenous injection of delta sleep-inducing peptide in man. Psychoneuroendocrinology. 1989;14(5):347-355. doi: 10.1016/0306-4530(89)90004-8 · PMID: 2554357 ↩
  18. Späth-Schwalbe E, Schäfer A, Uthgenannt D, et al. Delta-sleep-inducing peptide does not affect CRH and meal-induced ACTH and cortisol secretion. Psychoneuroendocrinology. 1995;20(3):231-237. doi: 10.1016/0306-4530(94)00050-k · PMID: 7777652 ↩
  19. Iyer KS, Marks GA, Kastin AJ, McCann SM. Evidence for a role of delta sleep-inducing peptide in slow-wave sleep and sleep-related growth hormone release in the rat. Proc Natl Acad Sci U S A. 1988;85(10):3653-3656. doi: 10.1073/pnas.85.10.3653 · PMID: 3368469 ↩
  20. Schneider-Helmert D, Gnirss F, Monnier M, et al. Acute and delayed effects of DSIP (delta sleep-inducing peptide) on human sleep behavior. Int J Clin Pharmacol Ther Toxicol. 1981;19(8):341-345. PMID: 6895513 ↩
  21. Schneider-Helmert D. DSIP in insomnia. Eur Neurol. 1984;23(5):358-363. doi: 10.1159/000115714 · PMID: 6391925 ↩
  22. Schneider-Helmert D, Hermann E, Schoenenberger GA. The use of DSIP (delta sleep-inducing peptide) in the correction of phase-shifted insomnia [in German]. Dtsch Med Wochenschr. 1987;112(23):922-925. doi: 10.1055/s-2008-1068167 · PMID: 3582201 ↩
  23. Dick P, Costa C, Fayolle K, et al. DSIP in the treatment of withdrawal syndromes from alcohol and opiates. Eur Neurol. 1984;23(5):364-371. doi: 10.1159/000115715 · PMID: 6548969 ↩
  24. Backmund M, Meyer K, Rothenhaeusler HB, et al. Opioid detoxification with delta sleep-inducing peptide: results of an open clinical trial. J Clin Psychopharmacol. 1998;18(3):257-258. doi: 10.1097/00004714-199806000-00016 · PMID: 9617990 ↩
  25. Pomfrett CJ, Dolling S, Anders NR, et al. Delta sleep-inducing peptide alters bispectral index, the electroencephalogram and heart rate variability when used as an adjunct to isoflurane anaesthesia. Eur J Anaesthesiol. 2009;26(2):128-134. doi: 10.1097/EJA.0b013e32831c8644 · PMID: 19142086 ↩
  26. ClinicalTrials.gov API search for "delta sleep-inducing peptide" OR DSIP OR emideltide, run October 28, 2026 (0 studies). clinicaltrials.gov ↩
  27. Popovich IG, Voitenkov BO, Anisimov VN, et al. Effect of delta-sleep inducing peptide-containing preparation Deltaran on biomarkers of aging, life span and spontaneous tumor incidence in female SHR mice. Mech Ageing Dev. 2003;124(6):721-731. doi: 10.1016/s0047-6374(03)00082-4 · PMID: 12782416 ↩
  28. U.S. Food and Drug Administration. Certain Bulk Drug Substances for Use in Compounding that May Present Significant Safety Risks (“Emideltide (DSIP)” under “Bulk drug substances nominated but withdrawn”). Updated April 22, 2026; checked October 28, 2026. fda.gov ↩
  29. Office of Information and Regulatory Affairs. Pending EO 12866 Regulatory Review: Interim Access Policy for Compounding Using Certain Peptides (RIN 0910-ZD94; HHS/FDA; received October 14, 2026; still pending when checked October 28, 2026). reginfo.gov ↩
  30. Vidal Russia drug reference. Deltaran (delta-sleep peptide): registration LP-No.(016126)-(RG-RU) of July 31, 2026, non-prescription; indications in combination therapy: stress-induced states, alcohol withdrawal syndrome. Checked October 28, 2026. vidal.ru ↩
  31. World Anti-Doping Agency. The 2027 Prohibited List (in force January 1, 2027): DSIP is not named; class S0 covers pharmacological substances with no current approval by any governmental regulatory health authority for human therapeutic use, including peptides. Checked October 28, 2026. wada-ama.org ↩

For catalog details, see the Genovare DSIP 50mg AQ pen. For editorial standards, continue to the editorial policy.

Related Research

Catalog Genovare DSIP 50mg AQ Pen→ Research DSIP Research Review→ Pineal Peptide Epitalon Benefits & Side Effects→ Neuropeptide Selank Peptide Research→ Neuropeptide Semax Peptide Research→ Regulation FDA Peptides 2026→ Catalog Research Peptide Catalog→